Press Release – New York, NY – February 5, 2025 – Sichenzia Ross Ference Carmel LLP announced today that it represented BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, in a best-efforts public offering of 762,500 common shares at a public offering price of $4.00 per share. Total gross proceeds from the offering, before deducting placement agent fees and other offering expenses, were $3.05 million.
The SRFC team was led by partners Gregory Sichenzia and Avital Perlman and associates Christian Lichtenberger and Benasz Hansotia
